Enhancing Parkinson’s Disease Treatment: Synergistic Effects of NBP and DA Using Liposomal Co-Delivery
Introduction
Table of Contents
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. The aging population and younger onset of PD mean that the incidence and mortality rates of PD will likely rise in the coming years. In China, by 2030, over half of the global PD patients may reside there. The main features of PD include the loss of dopaminergic neurons in the substantia nigra and the buildup of Lewy bodies containing misfolded α-synuclein.
Current treatments for PD primarily alleviate symptoms without halting disease progression. Research suggests that factors like oxidative stress, mitochondrial dysfunction, toxic protein aggregation, and inflammation contribute to PD. Because of this complexity, single-factor treatments may not be effective, indicating that drug combination strategies could be beneficial.
Drug Treatments for PD
Current drug regimens focus on dopamine (DA) replacement using levodopa (L-DOPA), the main treatment for PD. However, only a small fraction of L-DOPA crosses the blood-brain barrier (BBB) and is converted to DA. Despite its effectiveness in relieving symptoms, it does not prevent neurodegeneration.
3-n-Butylphthalide (NBP), derived from celery seeds, shows promise in treating ischemic stroke. It has various beneficial effects, including reducing neuroinflammation and apoptosis, promoting α-synuclein degradation, and repairing neuronal damage. NBP has been associated with reducing dopaminergic neuron loss in PD models. Combining NBP and DA may enhance therapeutic effects.
Drug Delivery Challenges
Conventional drugs often struggle to penetrate the BBB and lack targeted distribution within the brain. A co-delivery system using nanocarriers could improve absorption and distribution of combined therapies. Liposomes, made from biocompatible materials, are ideal carriers due to their ability to load both hydrophilic and lipophilic drugs.
In this study, we created a liposomal co-delivery system, (NBP+DA)-Lips-RVG29. This system incorporates RVG29, a peptide that binds specifically to acetylcholine receptors in the brain, facilitating drug delivery across the BBB. We evaluated the system’s physicochemical properties, therapeutic efficiency, and mechanisms in vitro and in vivo.
Materials and Methods
Materials
RVG29 peptide, DA, and NBP were sourced from reputable suppliers. Cell lines used included PC12 (dopaminergic), bEnd.3 (endothelial), and JAWS II (dendritic cells). Male Kunming mice and Sprague-Dawley rats were used in preclinical tests.
Cell and Animal Models
PC12 cells were treated with 6-OHDA to simulate PD. Viability, intracellular reactive oxygen species (ROS), and apoptosis were measured to assess drug effects.
Liposome Preparation and Characterization
Liposomes were created using a thin-film hydration method. RVG29 was conjugated to enhance brain targeting. Drug loading capacity and release profiles were evaluated using established techniques.
In Vitro Studies
We examined the therapeutic effects of the liposomal system on PC12 cells exposed to 6-OHDA, assessing cell viability and apoptosis. The mechanism of cellular uptake was explored using various inhibitors and flow cytometry.
In Vivo Studies
Pharmacokinetic profiles of the liposomal formulations were established in rats. Biodistribution and therapeutic efficacy were studied in PD mouse models after consecutive treatments.
Results and Discussion
Effects of NBP and DA
The combination of NBP and DA showed significant improvement in cell viability and reduced apoptosis compared to single-agent therapies. The optimal NBP:DA ratio was found to be 1:1.
Liposomal System Efficiency
(NBP+DA)-Lips-RVG29 was successfully formulated. In vitro release profiles indicated sustained drug release compared to free forms. The system demonstrated effective cellular uptake in PC12 cells, mediated by RVG29.
BBB Penetration
The modified liposomes showed enhanced permeability across a cell-based BBB model, indicating their potential to reach the brain effectively.
In Vivo Efficacy
In vivo studies demonstrated that (NBP+DA)-Lips-RVG29 significantly improved cognitive and motor functions in PD models. Increased levels of DA in the brain and reduced α-synuclein accumulation were observed.
Safety Assessment
The formulated system exhibited good safety profiles. No substantial changes in blood parameters or organ histology were noted after multiple dosing.
Conclusion
The findings suggest that the combination of NBP and DA in a targeted liposomal formulation enhances therapeutic effects in Parkinson’s disease. This innovative approach could provide a significant advancement in treating this complex neurological disorder. Further studies are warranted to establish long-term efficacy and safety profiles.